Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

CAMBRIDGE, Mass., March 16, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic ...

After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with an intrathecal formulation intended for older patients.

Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions ...

Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory filings ...

THE WEEK’S MOST POPULAR SONGS RANKED BY ROCK AND ALTERNATIVE RADIO AIRPLAY AUDIENCE IMPRESSIONS, AS MEAURED BY MEDIABASE AND PROVIDED BY LUMINATE. STATIONS ARE ELECTRONICALLY MONITORED 24 HOURS ...

Here is your 2025 hard rock + metal album release calendar and all of this week's newest albums! Each week is loaded with new rock and metal releases and keeping track of it all can be pretty ...

After hours: March 21 at 7:05:05 PM EDT Loading Chart for SRRK ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...